Financial Performance - The company reported a revenue of RMB 285,644,000 for the six months ended June 30, 2020, a decrease of 4.2% compared to RMB 299,404,000 for the same period in 2019[5]. - Gross profit for the six months ended June 30, 2020, was RMB 243,274,000, down from RMB 248,926,000 in 2019, reflecting a gross margin of approximately 85.2%[5]. - The net profit attributable to shareholders for the six months ended June 30, 2020, was RMB 51,686,000, compared to RMB 53,473,000 in the same period of 2019, representing a decline of 3.3%[5]. - For the six months ended June 30, 2020, the total revenue was RMB 307,735,000, a decrease of 3.4% compared to RMB 320,411,000 for the same period in 2019[21]. - The pharmaceutical sales amounted to RMB 285,644,000 for the six months ended June 30, 2020, down from RMB 299,404,000 in the previous year, representing a decline of 4.8%[21]. - The basic earnings per share for the six months ended June 30, 2020, were RMB 51,686,000, compared to RMB 53,473,000 for the same period in 2019, reflecting a decrease of 3.3%[28]. - The operating profit for the six months ended June 30, 2020, was not explicitly stated but is derived from the revenue figures and expenses reported[28]. - The company reported other income of RMB 22,091,000 for the six months ended June 30, 2020, compared to RMB 21,007,000 in the same period of 2019, showing a slight increase of 5.2%[5]. - The company’s operating expenses decreased to RMB 126,178,000 for the six months ended June 30, 2020, from RMB 182,650,000 in 2019, indicating a reduction of 30.9%[5]. - The company’s financial expenses for the six months ended June 30, 2020, were RMB 61,844,000, slightly down from RMB 62,985,000 in the previous year[5]. Assets and Liabilities - The company’s total assets as of June 30, 2020, amounted to RMB 1,419,857,000, an increase from RMB 1,398,922,000 as of December 31, 2019[10]. - Current liabilities totaled RMB 1,334,647,000 as of June 30, 2020, compared to RMB 1,283,605,000 at the end of 2019, indicating an increase in short-term obligations[10]. - The company’s equity increased to RMB 1,290,219,000 as of June 30, 2020, from RMB 1,238,533,000 as of December 31, 2019, reflecting a growth of 4.2%[12]. - The total assets related to property, plant, and equipment increased to RMB 147,617,000 as of June 30, 2020, from RMB 145,242,000 at the end of 2019[32]. - Inventory as of June 30, 2020, was RMB 48,020,000, down from RMB 51,239,000 as of December 31, 2019[41]. - Trade receivables as of June 30, 2020, totaled RMB 247,670,000, a decrease from RMB 260,154,000 as of December 31, 2019[43]. Shareholder Information - As of June 30, 2020, Mr. Zhang Hong holds 101,937,000 shares, representing 26.29% of domestic shares and 18.19% of total registered capital[58]. - Mr. Zhang Xiaoguang owns 42,315,000 shares, accounting for 10.91% of domestic shares and 7.55% of total registered capital[58]. - Huinan County Financial Investment Co., Ltd. holds 81,975,000 shares, which is 21.14% of domestic shares and 14.63% of total registered capital[62]. - Mr. Chen Jingwei owns 29,520,000 H shares, representing 17.11% of total registered capital[64]. Corporate Governance - The company has adopted a code of conduct for securities trading that meets or exceeds the standards set by GEM Listing Rules[65]. - The audit committee consists of three independent non-executive directors, ensuring oversight of financial procedures and internal controls[67]. - The company has not established any arrangements for directors to acquire rights through the purchase of shares or bonds[59]. - The chairman and CEO roles are held by Mr. Zhang Hong, which the board believes does not affect accountability or independent decision-making[66]. Employee Information - The company had 856 employees as of June 30, 2020, a decrease from 870 employees on June 30, 2019[70]. Dividends and Reinvestment - The company has not declared any dividends for the current period, maintaining a focus on reinvestment[5]. - The company did not recommend any interim dividend for the six months ended June 30, 2020, consistent with the previous year[31]. Operational Focus - The company’s operations are solely focused on the production and distribution of traditional Chinese medicine and pharmaceutical products within China[21]. - The company upgraded production facilities, enhancing capacity to meet market demand, and completed the construction and commissioning of a new solid dosage drug workshop[50]. - The company is focused on developing potential business opportunities to drive growth and achieve better results in the future[57].
吉林长龙药业(08049) - 2020 - 中期财报